United States - English - NLM (National Library of Medicine)

j. a. cosmetics u.s. inc - oxybenzone (unii: 95oos7ve0y) (oxybenzone - unii:95oos7ve0y), octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51) - oxybenzone 5 g in 100 g - purpose: sunscreen uses: helps prevent sunburn

United States - English - NLM (National Library of Medicine)

j. a. cosmetics u.s. inc - oxybenzone (unii: 95oos7ve0y) (oxybenzone - unii:95oos7ve0y), octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51) - oxybenzone 3.5 g in 100 g - purpose : sunscreen uses: help prevent sunburn

United States - English - NLM (National Library of Medicine)

hangzhou facecare cosmetics co., ltd. - oxybenzone (unii: 95oos7ve0y) (oxybenzone - unii:95oos7ve0y), octinoxate (unii: 4y5p7mud51) (octinoxate - unii:4y5p7mud51) - oxybenzone 4.5 g in 100 g - purpose: sunscreen uses: applying on lip area helps prevent sunburn

United States - English - NLM (National Library of Medicine)

clinique laboratories inc - oxybenzone (unii: 95oos7ve0y) (oxybenzone - unii:95oos7ve0y), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w), avobenzone (unii: g63qqf2nox) (avobenzone - unii:g63qqf2nox) - oxybenzone 5.0 ml in 100 ml

United States - English - NLM (National Library of Medicine)

bentley laboratories, llc - oxybenzone (unii: 95oos7ve0y) (oxybenzone - unii:95oos7ve0y), padimate o (unii: z11006cmuz) (padimate o - unii:z11006cmuz) - oxybenzone 0.1275 g in 4.25 g - sunscreen - helps prevent sunburn lips on damaged or broken skin if rash develops

United States - English - NLM (National Library of Medicine)

clinique laboratories inc - oxybenzone (unii: 95oos7ve0y) (oxybenzone - unii:95oos7ve0y), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w), avobenzone (unii: g63qqf2nox) (avobenzone - unii:g63qqf2nox) - oxybenzone 5.0 ml in 100 ml

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dechra veterinary products (australia) pty. ltd. - oxybenzone - unknown - oxybenzone uv screen active 0.0 - active constituent

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

troy laboratories pty ltd - oxybenzone - unknown - oxybenzone uv screen active 0.0 - active constituent

United States - English - NLM (National Library of Medicine)

jazz pharmaceuticals, inc. - sodium oxybate (unii: 7g33012534) (oxybate - unii:30iw36w5b2), calcium oxybate (unii: 8w24syd6zi) (oxybate - unii:30iw36w5b2), potassium oxybate (unii: s8nkf3h3kt) (oxybate - unii:30iw36w5b2), magnesium oxybate (unii: g983hlv265) (oxybate - unii:30iw36w5b2) - xywav is indicated for the treatment of cataplexy or excessive daytime sleepiness (eds) in patients 7 years of age and older with narcolepsy. xywav is indicated for the treatment of idiopathic hypersomnia (ih) in adults. xywav is contraindicated for use in: risk summary there are no adequate data on the developmental risk associated with the use of xywav or sodium oxybate in pregnant women. oral administration of sodium oxybate to pregnant rats (0, 150, 350, or 1,000 mg/kg/day) or rabbits (0, 300, 600, or 1,200 mg/kg/day) throughout organogenesis produced no clear evidence of developmental toxicity; however, oral administration to rats throughout pregnancy and lactation resulted in increased stillbirths and decreased offspring postnatal viability and growth, at a clinically relevant dose [see data] . in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. the background risk of major birth defec

United States - English - NLM (National Library of Medicine)

avadel cns pharmaceuticals, llc - sodium oxybate (unii: 7g33012534) (4-hydroxybutanoic acid - unii:30iw36w5b2) - lumryz is indicated for the treatment of cataplexy or excessive daytime sleepiness (eds) in adults with narcolepsy. lumryz is contraindicated for use in:            ●   combination with sedative hypnotics [see warnings and precautions (5.1)]            ●   combination with alcohol [see warnings and precautions (5.1)]            ●   patients with succinic semialdehyde dehydrogenase deficiency [see clinical pharmacology (12.3)] risk summary there are no adequate data on the developmental risk associated with the use of sodium oxybate in pregnant women. oral administration of sodium oxybate to pregnant rats (150, 350, or 1,000 mg/kg/day) or rabbits (300, 600, or 1,200 mg/kg/day) throughout organogenesis produced no clear evidence of developmental toxicity; however, oral administration to rats throughout pregnancy and lactation resulted in increased stillbirths and decreased offspring postnatal viability and growth, at a clinically relevant dose [see data] . in the u.s. general population, the estimated backgroun